Credit Suisse’s Maravai LifeSciences MRVI Stock Holding History

Credit Suisse’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$1.05M	Hold	120,555	–	–	﹤0.01%	2236
2023 Q4	$790K	Buy	120,555 +8,197	+7%	+$53K	﹤0.01%	2486
2023 Q3	$1.12M	Sell	112,358 -3,990	-3%	-$43.8K	﹤0.01%	2230
2023 Q2	$1.45M	Buy	116,348 +4,158	+4%	+$56.1K	﹤0.01%	2137
2023 Q1	$1.57M	Buy	112,190 +3,991	+4%	+$57.3K	﹤0.01%	2021
2022 Q4	$1.55M	Sell	108,199 -1,182	-1%	-$18.6K	﹤0.01%	2035
2022 Q3	$2.79M	Buy	109,381 +3,181	+3%	+$79.8K	﹤0.01%	1628
2022 Q2	$3.02M	Sell	106,200 -36,683	-26%	-$1.16M	﹤0.01%	1630
2022 Q1	$5.04M	Buy	142,883 +47,223	+49%	+$1.58M	﹤0.01%	1437
2021 Q4	$4.01M	Sell	95,660 -142,350	-60%	-$5.77M	﹤0.01%	2203
2021 Q3	$11.7M	Buy	238,010 +171,725	+259%	+$8.38M	0.01%	1428
2021 Q2	$2.77M	Buy	+66,285	New	+$2.57M	﹤0.01%	2586

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Credit Suisse's MRVI Position: Q1 2024 in Review

Credit Suisse held its Maravai LifeSciences (MRVI) position steady in Q1 2024 at 120,555 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2236.

Credit Suisse first reported a position in MRVI in Q2 2021 and has held it in 12 quarters since. The position peaked at $11.7M in Q3 2021. 210 funds tracked by Wall St. Rank hold MRVI as of Q1 2024.

Credit Suisse held 120,555 shares of Maravai LifeSciences worth $1.05M as of Q1 2024.
Credit Suisse left its Maravai LifeSciences share count unchanged in Q1 2024.
Maravai LifeSciences made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2236 holding.
Credit Suisse first reported a position in Maravai LifeSciences in Q2 2021 and has held it in 12 quarters since.
Credit Suisse's Maravai LifeSciences position peaked at $11.7M in Q3 2021.
210 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.